ArticleCureus2026
Extranodal Natural Killer/T-cell Lymphoma With Skin Involvement: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm derived from cytotoxic T cells or natural killer (NK) cells, with higher prevalence in Asia and Latin America. Epstein-Barr virus (EBV) infection plays a crucial role in its pathogenesis, being detected in most cases through in situ hybridization for EBV-encoded RNA (EBER). ENKTL predominantly affects men between 40 and 50 years of age, mainly involving the upper aerodigestive tract, particularly the nose and nasopharynx. However, it can also present in extranasal sites, where it tends to behave more aggressively. Clinical manifestations include cutaneous lesions with variable presentations that often mimic infections, delaying diagnosis. In limited-stage disease, radiotherapy (RT) is the treatment of choice, while advanced disease requires chemotherapy regimens, although no universally accepted standard protocol currently exists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.